Previous 10 | Next 10 |
home / stock / tbpmf / tbpmf news
Company to resume clinical trial in advanced cancer patients with uncontrolled pain Tetra engages leading clinical collaborator to run Plenitude trial in the U.S. OTTAWA, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (TSX-V: TBP) (OTCQB: TBPMF), a leader in...
OTTAWA, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (TSX-V: TBP) (OTCQB: TBPMF), a leader in drug discovery and development for cannabinoid-based therapeutics, today announced its subsidiary, 2714140 Ontario Inc., has secured financing of CAD $3,000,000 in the form of conve...
OTTAWA, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“ Tetra ” or “ TBP ”) is pleased to announce that the Corporation has become a member of BIOTECanada, a national industry association with over 200 members that represents Canada’s health, ...
OTTAWA, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (TSX-V) (OTCQB: TBPMF), a leader in drug discovery and development for cannabinoid-based therapeutics, today confirmed its regulatory strategy of its CAUMZ TM (PPP011) inhalation drug product and provided additional updat...
Azevedos To Commercialize Awaye™ in Portugal, Tunisia and Mozambique in Q1 2020 Tetra to submit two non-prescription DIN applications in Canada Tetra to commercialize non-prescription drugs in USA OTTAWA, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Tetra Natural Health (...
OTTAWA, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“ Tetra ” or “ TBP ”) today provides an update on its initiatives to bring its Caumz ® (PPP011) inhalation drug product to the market. The previous financing has allowed Tetra to ...
U.S. Food and Drug Administration (FDA) allows evaluation of CAUMZ Kit as a combination drug/device product, providing clarity on regulatory approval pathway This is a first step in the regulatory strategy to bring CAUMZ Kit to the market with additional FDA guidance anticipated by en...
OTTAWA, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., (TSX-V: TBP) (OTCQB: TBPMF), a leader in drug discovery and development for cannabinoid-based therapeutics, today announced it has signed an agreement with Thorne Research Inc. and Onegevity Health LLC to form a joint venture,...
ORLEANS, Ontario, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc., a leader in drug discovery and development for cannabinoid-based therapeutics, announced today the company has engaged LifeSci Advisors LLC, a leading investor relations consultancy serving life science companies, an...
ORLEANS, Ontario, July 30, 2019 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) is pleased to announce that, after successfully completing a prospectus offering for aggregate gross proceeds of $8,050,000 on July 12, 2019 (the ...
News, Short Squeeze, Breakout and More Instantly...
Tetra Bio-Pharma Inc Company Name:
TBPMF Stock Symbol:
OTCMKTS Market:
Tetra Bio-Pharma Inc Website:
(TheNewswire) Montreal – TheNewswire - August 1, 2023 – Tetra Bio-Pharma Inc. (“ Tetra ” or the “ Company ”) ( TSX:TBP ) ( OTC:TBPMF ) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development announced that...
(TheNewswire) MONTREAL, QUEBEC – TheNewswire – May 11, 2023 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTC:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development, today announced it has cancelled its New Drug Subm...
(TheNewswire) Montreal, QC - TheNewswire - March 10, 2023 - Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX:TBP) (OTC:TBPMF) (FRA:JAM1) , a leader in cannabinoid-derived drug discovery and development is pleased to announce Health Canada h...